Reviews in Endocrine and Metabolic Disorders

, Volume 13, Issue 4, pp 289–299 | Cite as

Endometrial haemostasis and menstruation

  • Joanna Davies
  • Rezan A. Kadir


Under normal physiological circumstances menstruation is a highly regulated, complex process that is under strict hormonal control. During normal menstruation, progesterone withdrawal initiates menstruation. The cessation of menstrual bleeding is achieved by endometrial haemostasis via platelet aggregation, fibrin deposition and thrombus formation. Local endocrine, immunological and haemostatic factors interact at a molecular level to control endometrial haemostasis. Tissue factor and thrombin play a key role locally in the cessation of menstrual bleeding through instigation of the coagulation factors. On the other hand, fibrinolysis prevents clot organisation within the uterine cavity while plasminogen activator inhibitors (PAI) and thrombin-activatable fibrinolysis inhibitors control plasminogen activators and plasmin activity. Abnormalities of uterine bleeding can result from imbalance of the haemostatic factors. The most common abnormality of uterine bleeding is heavy menstrual bleeding (HMB). Modern research has shown that an undiagnosed bleeding disorder, in particular von Willebrand disease (VWD) and platelet function disorders, can be an underlying cause of HMB. This has led to a change in the approach to the management of HMB. While full haemostatic assessment is not required for all women presenting with HMB, menstrual score and bleeding score can help to discriminate women who are more likely to have a bleeding disorder and benefit from laboratory haemostatic evaluation. Haemostatic agents (tranexamic acid and DDAVP) enhance systemic and endometrial haemostasis and are effective in reducing menstrual blood loss in women with or without bleeding disorders. Further research is required to enhance our understanding of the complex interactions of haemostatic factors in general, and specifically within the endometrium. This will lead to the development of more targeted interventions for the management of abnormal uterine bleeding in the future.


Endometrial haemostasis Uterine Bleeding Menstruation Coagulation 


  1. 1.
    Lee CA, Kadir RA, Kouides PA, Edlund M. Inherited bleeding disorders in women. 2009.CrossRefGoogle Scholar
  2. 2.
    von Willebrand E. Hereditar pseudohemofili. Finska Larkasallskapets Handl. 1926;67:7–112.Google Scholar
  3. 3.
    Furie B, Furie BC. Mechanisms of thrombus formation. N Engl J Med. 2008;359(9):938–49. doi: 10.1056/NEJMra0801082.PubMedCrossRefGoogle Scholar
  4. 4.
    Hoffbrand AV, Moss PAH, Pettit JE (2006) Essential haematology. 6th ed. Blackwell Publishing Ltd.Google Scholar
  5. 5.
    Lockwood CJ. Mechanisms of normal and abnormal endometrial bleeding. Menopause. 2011;18(4):408–11. doi: 10.1097/GME.0b013e31820bf288.PubMedCrossRefGoogle Scholar
  6. 6.
    Christiaens GC, Sixma JJ, Haspels AA. Morphology of haemostasis in menstrual endometrium. Br J Obstet Gynaecol. 1980;87(5):425–39.PubMedCrossRefGoogle Scholar
  7. 7.
    Christiaens GC, Sixma JJ, Haspels AA. Hemostasis in menstrual endometrium: a review. Obstet Gynecol Surv. 1982;37(5):281–303.PubMedCrossRefGoogle Scholar
  8. 8.
    Koh SC, Wong PC, Yuen R, Chua SE, Ng BL, Ratnam SS. Concentration of plasminogen activators and inhibitor in the human endometrium at different phases of the menstrual cycle. J Reprod Fertil. 1992;96(2):407–13.PubMedCrossRefGoogle Scholar
  9. 9.
    Albrechtsen OK. The fibrinolytic activity of the human endometrium. Acta Endocrinol (Copenh). 1956;23(2):207–18.Google Scholar
  10. 10.
    Cole SK, Clarkson AR. Menstrual blood loss and fibrin degradation products. Br Med J. 1972;1(5792):78–9.PubMedCrossRefGoogle Scholar
  11. 11.
    Casslen B, Astedt B. Fibrinolytic activity of human uterine fluid. Acta Obstet Gynecol Scand. 1981;60(1):55–8.PubMedCrossRefGoogle Scholar
  12. 12.
    Hallberg L, Nilsson L. Determination of menstrual blood loss. Scand J Clin Lab Invest. 1964;16:244–8.PubMedCrossRefGoogle Scholar
  13. 13.
    Kadir RA, Economides DL, Sabin CA, Pollard D, Lee CA. Assessment of menstrual blood loss and gynaecological problems in patients with inherited bleeding disorders. Haemophilia. 1999;5(1):40–8.PubMedCrossRefGoogle Scholar
  14. 14.
    Warner PE, Critchley HO, Lumsden MA, Campbell-Brown M, Douglas A, Murray GD. Menorrhagia II: is the 80-mL blood loss criterion useful in management of complaint of menorrhagia? Am J Obstet Gynecol. 2004;190(5):1224–9. doi: 10.1016/j.ajog.2003.11.016.PubMedCrossRefGoogle Scholar
  15. 15.
    Higham JM, O’Brien PM, Shaw RW. Assessment of menstrual blood loss using a pictorial chart. Br J Obstet Gynaecol. 1990;97(8):734–9.PubMedCrossRefGoogle Scholar
  16. 16.
    Shaw RW, Brickley MR, Evans L, Edwards MJ. Perceptions of women on the impact of menorrhagia on their health using multi-attribute utility assessment. Br J Obstet Gynaecol. 1998;105(11):1155–9.PubMedCrossRefGoogle Scholar
  17. 17.
    Clarke A, Black N, Rowe P, Mott S, Howle K. Indications for and outcome of total abdominal hysterectomy for benign disease: a prospective cohort study. Br J Obstet Gynaecol. 1995;102(8):611–20.PubMedCrossRefGoogle Scholar
  18. 18.
    Sinclair DC, Mastroyannis A, Taylor HS. Leiomyoma simultaneously impair endometrial BMP-2-mediated decidualization and anticoagulant expression through secretion of TGF-beta3. J Clin Endocrinol Metab. 2011;96(2):412–21. doi: 10.1210/jc.2010-1450.PubMedCrossRefGoogle Scholar
  19. 19.
    Livingstone M, Fraser IS. Mechanisms of abnormal uterine bleeding. Hum Reprod Update. 2002;8(1):60–7.PubMedCrossRefGoogle Scholar
  20. 20.
    Kadir RA, Economides DL, Sabin CA, Owens D, Lee CA. Frequency of inherited bleeding disorders in women with menorrhagia. Lancet. 1998;351(9101):485–9. doi: 10.1016/S0140-6736(97)08248-2.PubMedCrossRefGoogle Scholar
  21. 21.
    Sadler JE, Budde U, Eikenboom JC, Favaloro EJ, Hill FG, Holmberg L, et al. Update on the pathophysiology and classification of von Willebrand disease: a report of the subcommittee on von willebrand factor. J Thromb Haemost. 2006;4(10):2103–14. doi: 10.1111/j.1538-7836.2006.02146.x.PubMedCrossRefGoogle Scholar
  22. 22.
    Lak M, Peyvandi F, Mannucci PM. Clinical manifestations and complications of childbirth and replacement therapy in 385 Iranian patients with type 3 von Willebrand disease. Br J Haematol. 2000;111(4):1236–9.PubMedCrossRefGoogle Scholar
  23. 23.
    Plug I, Mauser-Bunschoten EP, Brocker-Vriends AH, van Amstel HK, van der Bom JG, van Diemen-Homan JE, et al. Bleeding in carriers of hemophilia. Blood. 2006;108(1):52–6. doi: 10.1182/blood-2005-09-3879.PubMedCrossRefGoogle Scholar
  24. 24.
    Bevan JA, Maloney KW, Hillery CA, Gill JC, Montgomery RR, Scott JP. Bleeding disorders: a common cause of menorrhagia in adolescents. J Pediatr. 2001;138(6):856–61. doi: 10.1067/mpd.2001.113042.PubMedCrossRefGoogle Scholar
  25. 25.
    George JN, Caen JP, Nurden AT. Glanzmann’s thrombasthenia: the spectrum of clinical disease. Blood. 1990;75(7):1383–95.PubMedGoogle Scholar
  26. 26.
    Lopez JA, Andrews RK, Afshar-Kharghan V, Berndt MC. Bernard-Soulier syndrome. Blood. 1998;91(12):4397–418.PubMedGoogle Scholar
  27. 27.
    James AH. More than menorrhagia: a review of the obstetric and gynaecological manifestations of bleeding disorders. Haemophilia. 2005;11(4):295–307. doi: 10.1111/j.1365-2516.2005.01108.x.PubMedCrossRefGoogle Scholar
  28. 28.
    Tosetto A, Rodeghiero F, Castaman G, Goodeve A, Federici AB, Batlle J, et al. A quantitative analysis of bleeding symptoms in type 1 von Willebrand disease: results from a multicenter European study (MCMDM-1 VWD). J Thromb Haemost. 2006;4(4):766–73. doi: 10.1111/j.1538-7836.2006.01847.x.PubMedCrossRefGoogle Scholar
  29. 29.
    Shankar M, Lee CA, Sabin CA, Economides DL, Kadir RA. von Willebrand disease in women with menorrhagia: a systematic review. BJOG. 2004;111(7):734–40. doi: 10.1111/j.1471-0528.2004.00176.x.PubMedCrossRefGoogle Scholar
  30. 30.
    Minjarez DA, Bradshaw KD. Abnormal uterine bleeding in adolescents. Obstet Gynecol Clin North Am. 2000;27(1):63–78.PubMedCrossRefGoogle Scholar
  31. 31.
    Philipp CS, Dilley A, Miller CH, Evatt B, Baranwal A, Schwartz R, et al. Platelet functional defects in women with unexplained menorrhagia. J Thromb Haemost. 2003;1(3):477–84.PubMedCrossRefGoogle Scholar
  32. 32.
    Miller CH, Philipp CS, Stein SF, Kouides PA, Lukes AS, Heit JA, et al. The spectrum of haemostatic characteristics of women with unexplained menorrhagia. Haemophilia. 2011;17(1):e223–9. doi: 10.1111/j.1365-2516.2010.02382.x.PubMedCrossRefGoogle Scholar
  33. 33.
    James AH, Kouides PA, Abdul-Kadir R, Edlund M, Federici AB, Halimeh S, et al. Von Willebrand disease and other bleeding disorders in women: consensus on diagnosis and management from an international expert panel. Am J Obstet Gynecol. 2009;201(1):12. doi: 10.1016/j.ajog.2009.04.024. e11-18.PubMedCrossRefGoogle Scholar
  34. 34.
    Rodeghiero F, Tosetto A, Abshire T, Arnold DM, Coller B, James P, et al. ISTH/SSC bleeding assessment tool: a standardized questionnaire and a proposal for a new bleeding score for inherited bleeding disorders. J Thromb Haemost. 2010;8(9):2063–5. doi: 10.1111/j.1538-7836.2010.03975.x.PubMedCrossRefGoogle Scholar
  35. 35.
    Philipp CS. Platelet disorders in adolescents. J Pediatr Adolesc Gynecol. 2010;23(6 Suppl):S11–4. doi: 10.1016/j.jpag.2010.08.012.PubMedCrossRefGoogle Scholar
  36. 36.
    Huq FY, Tvarkova K, Arafa A, Kadir RA. Menstrual problems and contraception in women of reproductive age receiving oral anticoagulation. Contraception. 2011;84(2):128–32. doi: 10.1016/j.contraception.2010.12.011.PubMedCrossRefGoogle Scholar
  37. 37.
    Michiels JJ, Schroyens W, Berneman Z, van der Planken M. Acquired von Willebrand syndrome type 1 in hypothyroidism: reversal after treatment with thyroxine. Clin Appl Thromb Hemost. 2001;7(2):113–5.PubMedCrossRefGoogle Scholar
  38. 38.
    Zervou S, Klentzeris LD, Old RW. Nitric oxide synthase expression and steroid regulation in the uterus of women with menorrhagia. Mol Hum Reprod. 1999;5(11):1048–54.PubMedCrossRefGoogle Scholar
  39. 39.
    Lockwood CJ, Krikun G, Runic R, Schwartz LB, Mesia AF, Schatz F. Progestin-epidermal growth factor regulation of tissue factor expression during decidualization of human endometrial stromal cells. J Clin Endocrinol Metab. 2000;85(1):297–301.PubMedCrossRefGoogle Scholar
  40. 40.
    Edlund M, Andersson E, Fried G. Progesterone withdrawal causes endothelin release from cultured human uterine microvascular endothelial cells. Hum Reprod. 2004;19(6):1272–80. doi: 10.1093/humrep/deh256.PubMedCrossRefGoogle Scholar
  41. 41.
    Krikun G, Lockwood CJ, Paidas MJ. Tissue factor and the endometrium: from physiology to pathology. Thromb Res. 2009;124(4):393–6. doi: 10.1016/j.thromres.2009.06.013.PubMedCrossRefGoogle Scholar
  42. 42.
    Agarwal U, El Sheikh S, Kulkarni A, Baff D, Kadir RA. Von Willebrand factor expression in endometrial endothelial cells in women with menorrhagia. Fertil Steril. 2010;94(6):2335–7. doi: 10.1016/j.fertnstert.2010.02.055.PubMedCrossRefGoogle Scholar
  43. 43.
    Edlund M, Blomback M, He S. On the correlation between local fibrinolytic activity in menstrual fluid and total blood loss during menstruation and effects of desmopressin. Blood Coagul Fibrinolysis. 2003;14(6):593–8. doi: 10.1097/01.mbc.0000061343.72909.8a.PubMedCrossRefGoogle Scholar
  44. 44.
    Gleeson N, Devitt M, Sheppard BL, Bonnar J. Endometrial fibrinolytic enzymes in women with normal menstruation and dysfunctional uterine bleeding. Br J Obstet Gynaecol. 1993;100(8):768–71.PubMedCrossRefGoogle Scholar
  45. 45.
    Chi C, Huq FY, Kadir RA. Levonorgestrel-releasing intrauterine system for the management of heavy menstrual bleeding in women with inherited bleeding disorders: long-term follow-up. Contraception. 2011;83(3):242–7. doi: 10.1016/j.contraception.2010.07.010.PubMedCrossRefGoogle Scholar
  46. 46.
    Zhu PD, Gu Z. Observation of the activity of factor VIII in the endometrium of women with regular menstrual cycles. Hum Reprod. 1988;3(3):273–5.PubMedGoogle Scholar
  47. 47.
    Zhu PD, Luo HZ, Shi WL, Wang JD, Cheng J, Xu RH, et al. Observation of the activity of factor VIII in the endometrium of women pre- and post-insertion of three types of IUDs. Contraception. 1991;44(4):367–84.PubMedCrossRefGoogle Scholar
  48. 48.
    Kadir RA. Menorrhagia: treatment options. Thromb Res. 2009;123 Suppl 2:S21–9. doi: 10.1016/S0049-3848(09)70005-2.PubMedCrossRefGoogle Scholar
  49. 49.
    James AH. Diagnosis and management of women with bleeding disorders–international guidelines and consensus from an international expert panel. Haemophilia. 2011;17 Suppl 1:3–5. doi: 10.1111/j.1365-2516.2011.02557.x.PubMedCrossRefGoogle Scholar
  50. 50.
    Gleeson NC, Buggy F, Sheppard BL, Bonnar J. The effect of tranexamic acid on measured menstrual loss and endometrial fibrinolytic enzymes in dysfunctional uterine bleeding. Acta Obstet Gynecol Scand. 1994;73(3):274–7.PubMedCrossRefGoogle Scholar
  51. 51.
    Dockeray CJ, Sheppard BL, Daly L, Bonnar J. The fibrinolytic enzyme system in normal menstruation and excessive uterine bleeding and the effect of tranexamic acid. Eur J Obstet Gynecol Reprod Biol. 1987;24(4):309–18.PubMedCrossRefGoogle Scholar
  52. 52.
    Bonnar J, Sheppard BL. Treatment of menorrhagia during menstruation: randomised controlled trial of ethamsylate, mefenamic acid, and tranexamic acid. BMJ. 1996;313(7057):579–82.PubMedCrossRefGoogle Scholar
  53. 53.
    Freeman EW, Lukes A, VanDrie D, Mabey RG, Gersten J, Adomako TL. A dose–response study of a novel, oral tranexamic formulation for heavy menstrual bleeding. Am J Obstet Gynecol. 2011;205(4):319. doi: 10.1016/j.ajog.2011.05.015. e311-317.PubMedCrossRefGoogle Scholar
  54. 54.
    Rodeghiero F, Castaman G, Mannucci PM. Prospective multicenter study on subcutaneous concentrated desmopressin for home treatment of patients with von willebrand disease and mild or moderate hemophilia A. Thromb Haemost. 1996;76(5):692–6.PubMedGoogle Scholar
  55. 55.
    Leissinger C, Becton D, Cornell Jr C, Cox Gill J. High-dose DDAVP intranasal spray (Stimate) for the prevention and treatment of bleeding in patients with mild haemophilia A, mild or moderate type 1 von Willebrand disease and symptomatic carriers of haemophilia A. Haemophilia. 2001;7(3):258–66.PubMedCrossRefGoogle Scholar
  56. 56.
    Kouides PA, Byams VR, Philipp CS, Stein SF, Heit JA, Lukes AS, et al. Multisite management study of menorrhagia with abnormal laboratory haemostasis: a prospective crossover study of intranasal desmopressin and oral tranexamic acid. Br J Haematol. 2009;145(2):212–20. doi: 10.1111/j.1365-2141.2009.07610.x.PubMedCrossRefGoogle Scholar
  57. 57.
    Edlund M, Blomback M, Fried G. Desmopressin in the treatment of menorrhagia in women with no common coagulation factor deficiency but with prolonged bleeding time. Blood Coagul Fibrinolysis. 2002;13(3):225–31.PubMedCrossRefGoogle Scholar
  58. 58.
    Cash JD, Gader AM, da Costa J. Proceedings: the release of plasminogen activator and factor VIII to lysine vasopressin, arginine vasopressin, I-desamino-8-d-arginine vasopressin, angiotensin and oxytocin in man. Br J Haematol. 1974;27(2):363–4.PubMedGoogle Scholar
  59. 59.
    Dunn AL, Powers JR, Ribeiro MJ, Rickles FR, Abshire TC. Adverse events during use of intranasal desmopressin acetate for haemophilia A and von Willebrand disease: a case report and review of 40 patients. Haemophilia. 2000;6(1):11–4.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2012

Authors and Affiliations

  1. 1.The Haemophilia Centre and Thrombosis UnitThe Royal Free HospitalLondonUK

Personalised recommendations